https://www.healthreportequatorialguinea.com/article/913218679-studies-highlight-advances-in-kidney-stone-prevention-and-anesthesia-free-stone-removal Health Report Equatorial Guinea en PressRelease 2026-05-16T16:00:00+00:00 Studies Highlight Advances in Kidney Stone Prevention and Anesthesia Free Stone Removal https://ml.globenewswire.com/media/ZDY3ODIzZDQtODRiNC00ZWMzLWIzYjEtYmJjZDNmZGRmNmVmLTEyNzYxOTAtMjAyNi0wNS0xNi1lbg==/tiny/American-Urological-Associatio.png https://www.healthreportequatorialguinea.com/article/913208702-new-studies-position-men-s-reproductive-health-as-an-early-indicator-of-overall-wellness Health Report Equatorial Guinea en PressRelease 2026-05-16T13:00:00+00:00 New Studies Position Men’s Reproductive Health as an Early Indicator of Overall Wellness https://ml.globenewswire.com/media/MzYzNDYwNWYtZDVjMS00ZmZkLWJjOWEtYTM1NjNhZWE1MTZmLTEyNzYxOTAtMjAyNi0wNS0xNi1lbg==/tiny/American-Urological-Associatio.png https://www.healthreportequatorialguinea.com/article/913199221-ipsen-presents-first-in-class-late-breaking-phase-ii-corabotase-data-in-glabellar-lines-showing-sustained-duration-of-effect-reinforced-by Health Report Equatorial Guinea en PressRelease 2026-05-16T12:00:00+00:00 Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction https://ml-eu.globenewswire.com/media/81292fcc-6b3a-4e4a-a083-ea4191bf920a/small/ipsen-notified-website-1200x628pix-500kb-max-jpg.jpg https://www.healthreportequatorialguinea.com/article/913199224-ipsen-pr-sente-les-derniers-r-sultats-d-une-tude-de-phase-ii-sur-la-corabotase-premi-re-de-sa-classe-concernant-les-rides-glabellaires-montrant Health Report Equatorial Guinea en PressRelease 2026-05-16T12:00:00+00:00 Ipsen présente les derniers résultats d'une étude de phase II sur la corabotase, première de sa classe, concernant les rides glabellaires, montrant une durée d'effet prolongée et un niveau de satisfaction constamment élevé chez les patients https://ml-eu.globenewswire.com/media/81292fcc-6b3a-4e4a-a083-ea4191bf920a/small/ https://www.healthreportequatorialguinea.com/article/913199218-impact-biotech-presents-updated-data-from-phase-3-enlighted-trial-of-padeliporfin-vtp-in-lg-utuc-at-aua-2026 Health Report Equatorial Guinea en PressRelease 2026-05-16T11:00:00+00:00 ImPact Biotech Presents Updated Data from Phase 3 ENLIGHTED Trial of Padeliporfin VTP in LG-UTUC at AUA 2026 https://ml-eu.globenewswire.com/media/68762066-1fff-4065-af45-d18da25273cd/small/impact-biotech-logo-final-resized-jpg.jpg https://www.healthreportequatorialguinea.com/article/913128555-regeneron-provides-update-on-phase-3-trial-of-fianlimab-lag-3-inhibitor-combination-in-first-line-unresectable-or-metastatic-melanoma Health Report Equatorial Guinea en PressRelease 2026-05-16T00:19:44+00:00 Regeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic Melanoma https://ml.globenewswire.com/media/add5ebc7-88c9-49dc-8834-abbb07c622d1/small/regeneron-logo-jpg.jpg https://www.healthreportequatorialguinea.com/article/913110919-update-next-generation-of-scientific-leaders-awarded-more-than-7-million-at-the-2026-regeneron-international-science-and-engineering-fair Health Report Equatorial Guinea en PressRelease 2026-05-15T21:56:33+00:00 UPDATE – Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair https://ml.globenewswire.com/media/d487359a-15a0-4e66-812a-4cdc7f2ef379/medium/congratulations-to-the-winners-of-the-regeneron-internationa.jpg https://www.healthreportequatorialguinea.com/article/913091624-range-impact-reports-1q-2026-financial-results Health Report Equatorial Guinea en PressRelease 2026-05-15T21:05:00+00:00 Range Impact Reports 1Q 2026 Financial Results https://ml.globenewswire.com/media/7d693e90-6bf7-4ad3-aac1-17d8d0044c9a/small/logo-png.png https://www.healthreportequatorialguinea.com/article/913091463-allarity-therapeutics-reports-first-quarter-2026-results-and-continued-stenoparib-development-in-multiple-cancers Health Report Equatorial Guinea en PressRelease 2026-05-15T20:30:00+00:00 Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers https://ml-eu.globenewswire.com/media/fd1e4c64-f0cf-40e0-a0c9-0be0d6dce544/small/allarity-full-color-rgb-2023jun07-png.png https://www.healthreportequatorialguinea.com/article/913092002-next-generation-of-scientific-leaders-awarded-more-than-7-million-at-the-2026-regeneron-international-science-and-engineering-fair Health Report Equatorial Guinea en PressRelease 2026-05-15T20:27:38+00:00 Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair https://ml.globenewswire.com/media/d487359a-15a0-4e66-812a-4cdc7f2ef379/medium/congratulations-to-the-winners-of-the-regeneron-internationa.jpg https://www.healthreportequatorialguinea.com/article/913091465-aktion-rinnen-und-aktion-re-der-biontech-se-stimmen-auf-der-ordentlichen-hauptversammlung-2026-allen-tagesordnungspunkten-zu Health Report Equatorial Guinea en PressRelease 2026-05-15T20:15:00+00:00 Aktionärinnen und Aktionäre der BioNTech SE stimmen auf der ordentlichen Hauptversammlung 2026 allen Tagesordnungspunkten zu https://ml-eu.globenewswire.com/media/b9e2e00e-f790-4d54-a01f-4c85716b01bd/small/ https://www.healthreportequatorialguinea.com/article/913091470-biontech-se-shareholders-approve-all-agenda-items-at-the-annual-general-meeting-2026 Health Report Equatorial Guinea en PressRelease 2026-05-15T20:15:00+00:00 BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026 https://ml-eu.globenewswire.com/media/b9e2e00e-f790-4d54-a01f-4c85716b01bd/small/190705-biontech-logo-rgb-dark-green-preferred-0-png.png https://www.healthreportequatorialguinea.com/article/913091580-enlivex-announces-receipt-of-nasdaq-minimum-bid-price-notification Health Report Equatorial Guinea en PressRelease 2026-05-15T20:10:00+00:00 Enlivex Announces Receipt of Nasdaq Minimum Bid Price Notification https://ml.globenewswire.com/media/27d4e006-8709-4fd1-8341-5b58381487d4/small/picture1-jpg.jpg https://www.healthreportequatorialguinea.com/article/913091479-4dmt-announces-new-employment-inducement-grants Health Report Equatorial Guinea en PressRelease 2026-05-15T20:05:00+00:00 4DMT Announces New Employment Inducement Grants https://ml.globenewswire.com/media/027d40cf-145a-47b2-a0b8-823759376823/small/logo-2x-png.png https://www.healthreportequatorialguinea.com/article/913091483-korro-bio-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4 Health Report Equatorial Guinea en PressRelease 2026-05-15T20:05:00+00:00 Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/d49fc3c4-5cf6-4b89-8434-2eadfff25c26/small/korro-logo-rgb-jpg.jpg https://www.healthreportequatorialguinea.com/article/913091515-candel-therapeutics-reports-extended-clinical-benefit-over-multiple-clinical-endpoints-in-patients-from-phase-3-trial-of-aglatimagene-besadenovec Health Report Equatorial Guinea en PressRelease 2026-05-15T20:05:00+00:00 Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting https://ml.globenewswire.com/media/8b82e1e3-4a67-4472-a7c8-05f9d24c9bb0/small/candel-logo-fullcolor-4-png.png https://www.healthreportequatorialguinea.com/article/913091553-plus-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-update-on-reyobiq-clinical-program-and-cnside-commercial Health Report Equatorial Guinea en PressRelease 2026-05-15T20:05:00+00:00 Plus Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update on REYOBIQ™ Clinical Program and CNSide® Commercial Rollout https://ml.globenewswire.com/media/92d7aa70-e37d-4870-bccf-d83b68ba5612/small/plus-logo-png.png https://www.healthreportequatorialguinea.com/article/913091573-rani-therapeutics-reports-first-quarter-2026-financial-results-provides-corporate-update-announces-cfo-transition Health Report Equatorial Guinea en PressRelease 2026-05-15T20:05:00+00:00 Rani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition https://ml.globenewswire.com/media/8ce7774c-3696-4aa1-8bcd-413805f0a642/small/rani-logo-jpg.jpg https://www.healthreportequatorialguinea.com/article/913091674-outlook-therapeutics-reports-second-quarter-fiscal-year-2026-financial-results-and-provides-corporate-update Health Report Equatorial Guinea en PressRelease 2026-05-15T20:05:00+00:00 Outlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update https://ml.globenewswire.com/media/cbff3302-f8d2-466a-beff-8c33252f9c70/small/otlk-png.png https://www.healthreportequatorialguinea.com/article/913091803-solana-company-reports-first-quarter-2026-financial-results Health Report Equatorial Guinea en PressRelease 2026-05-15T20:05:00+00:00 Solana Company Reports First Quarter 2026 Financial Results https://ml.globenewswire.com/media/1986b97e-8656-4213-9218-ae51324d696d/small/solana-company-main-black-png.png https://www.healthreportequatorialguinea.com/article/913091758-the-robotic-spine-institute-of-las-vegas-announces-dr-kornelis-poelstra-s-completion-of-2-000-robotic-spine-surgeries Health Report Equatorial Guinea en PressRelease 2026-05-15T19:49:42+00:00 The Robotic Spine Institute of Las Vegas Announces Dr. Kornelis Poelstra’s Completion of 2,000 Robotic Spine Surgeries https://ml.globenewswire.com/media/eaffdd13-f560-4e30-a943-88f95c74212a/medium/the-robotic-spine-institute-of-las-vegas-logo.jpg https://www.healthreportequatorialguinea.com/article/913072220-countdown-grant-explores-how-cells-remove-damaged-mitochondria-opening-new-possibilities-across-parkinson-s-chronic-disease-rare-disease-and Health Report Equatorial Guinea en PressRelease 2026-05-15T19:08:15+00:00 Countdown Grant Explores How Cells Remove Damaged Mitochondria — Opening New Possibilities Across Parkinson’s, Chronic Disease, Rare Disease, and Aging https://ml.globenewswire.com/media/4b0768b1-ff68-490a-a704-61680c06c761/small/countdown-logo-black-font-transparent-background-1-png.png https://www.healthreportequatorialguinea.com/article/913072150-next-generation-of-scientific-leaders-awarded-more-than-7-million-at-the-2026-regeneron-international-science-and-engineering-fair Health Report Equatorial Guinea en PressRelease 2026-05-15T18:09:52+00:00 Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair https://ml.globenewswire.com/media/add5ebc7-88c9-49dc-8834-abbb07c622d1/small/regeneron-logo-jpg.jpg https://www.healthreportequatorialguinea.com/article/913072101-sutter-health-and-santa-clara-university-to-launch-the-mark-mary-stevens-school-of-medicine Health Report Equatorial Guinea en PressRelease 2026-05-15T18:00:00+00:00 Sutter Health and Santa Clara University to Launch the Mark & Mary Stevens School of Medicine https://ml.globenewswire.com/media/NGQ5N2IyYzQtYmU4Zi00NjI1LWI1MmEtMzllMTJlN2UwMmRiLTUwMDE1MDYxNS0yMDI2LTA1LTE1LWVu/tiny/Sutter-Health.png https://www.healthreportequatorialguinea.com/article/913072106-studies-highlight-advances-in-bladder-cancer-care-and-emerging-environmental-risks Health Report Equatorial Guinea en PressRelease 2026-05-15T18:00:00+00:00 Studies Highlight Advances in Bladder Cancer Care and Emerging Environmental Risks https://ml.globenewswire.com/media/ODUwMzljZmYtNzk3Ny00NTdmLTk5YjEtZmI3MDljNDJhOWU2LTEyNzYxOTAtMjAyNi0wNS0xNS1lbg==/tiny/American-Urological-Associatio.png https://www.healthreportequatorialguinea.com/article/913055234-bladder-cancer-advocacy-network-discusses-why-bladder-cancer-demands-attention-now-with-yourupdatetv Health Report Equatorial Guinea en PressRelease 2026-05-15T17:10:15+00:00 Bladder Cancer Advocacy Network Discusses Why Bladder Cancer Demands Attention Now with YourUpdateTV https://ml.globenewswire.com/media/5115f449-412d-4a05-bbcb-add09b3f2838/small/blank-logo-png.png https://www.healthreportequatorialguinea.com/article/913054999-peer-reviewed-research-is-redefining-weight-loss-program-standards Health Report Equatorial Guinea en PressRelease 2026-05-15T17:00:00+00:00 Peer-Reviewed Research Is Redefining Weight Loss Program Standards https://ml.globenewswire.com/media/71842691-8451-4b00-bdc5-6fd621c7675f/small/medifast-logo-jpg-jpg.jpg https://www.healthreportequatorialguinea.com/article/913055023-peer-reviewed-research-shows-structured-meal-replacement-programs-support-visceral-fat-reduction-and-lean-mass-preservation Health Report Equatorial Guinea en PressRelease 2026-05-15T17:00:00+00:00 Peer-Reviewed Research Shows Structured Meal Replacement Programs Support Visceral Fat Reduction and Lean Mass Preservation https://ml.globenewswire.com/media/71842691-8451-4b00-bdc5-6fd621c7675f/small/medifast-logo-jpg-jpg.jpg https://www.healthreportequatorialguinea.com/article/913055026-ergodyne-launches-tool-belt-system-built-to-fight-gravity-and-poor-design Health Report Equatorial Guinea en PressRelease 2026-05-15T17:00:00+00:00 Ergodyne Launches Tool Belt System Built to Fight Gravity and Poor Design https://ml.globenewswire.com/media/NmVhNGU4YzAtMDMzZS00Njg1LWIyNTYtZThmMzNjNGE1ZDFiLTExODg4MTAtMjAyNi0wNS0xNS1lbg==/tiny/Ergodyne.png https://www.healthreportequatorialguinea.com/article/913054960-award-winning-medical-alert-system-bay-alarm-medical-appoints-jay-kolker-as-new-director-of-it Health Report Equatorial Guinea en PressRelease 2026-05-15T16:02:00+00:00 Award-winning Medical Alert System Bay Alarm Medical Appoints Jay Kolker as New Director of IT https://ml.globenewswire.com/media/532ee238-65a7-4192-a770-6c27d03c072f/small/bay-alarm-medical-logo.png https://www.healthreportequatorialguinea.com/article/913036917-prokidney-reports-first-quarter-2026-financial-results-and-business-highlights Health Report Equatorial Guinea en PressRelease 2026-05-15T15:45:00+00:00 ProKidney Reports First Quarter 2026 Financial Results and Business Highlights https://ml.globenewswire.com/media/7813087f-9f76-4dfa-bb9d-37d4299f3cf8/small/prokidney-company-logo-png.PNG https://www.healthreportequatorialguinea.com/article/913036680-studies-highlight-personalized-approaches-to-prostate-cancer-care-from-diet-and-surgery-to-public-awareness Health Report Equatorial Guinea en PressRelease 2026-05-15T15:30:00+00:00 Studies Highlight Personalized Approaches to Prostate Cancer Care, From Diet and Surgery to Public Awareness https://ml.globenewswire.com/media/ODQ5NmE5MjktMGY4Mi00MDI4LThlMGEtZWViMTdiOThmNGU0LTEyNzYxOTAtMjAyNi0wNS0xNS1lbg==/tiny/American-Urological-Associatio.png https://www.healthreportequatorialguinea.com/article/913036868-actress-jackie-tohn-got-results-nobody-wants-but-they-may-have-saved-her-life Health Report Equatorial Guinea en PressRelease 2026-05-15T15:00:00+00:00 Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life https://ml.globenewswire.com/media/3ded1260-ff18-4d40-8de4-52dbb033d4f2/medium/jackie-tohn.jpg https://www.healthreportequatorialguinea.com/article/913036617-methanol-engines-market-to-hit-5-39-billion-by-2035-unlock-growth-opportunity Health Report Equatorial Guinea en PressRelease 2026-05-15T14:30:00+00:00 Methanol Engines Market to Hit $5.39 Billion by 2035 – Unlock Growth Opportunity https://ml.globenewswire.com/media/afcc5182-4ae0-43a8-a965-4351d590b7ed/small/mnm-logo-tm-jpg-jpg.JPG https://www.healthreportequatorialguinea.com/article/913036634-ei4change-expands-its-emotional-intelligence-learning-platform-with-interactive-tools-for-real-workplace-situations Health Report Equatorial Guinea en PressRelease 2026-05-15T14:00:00+00:00 Ei4Change Expands Its Emotional Intelligence Learning Platform with Interactive Tools for Real Workplace Situations https://ml.globenewswire.com/media/6f3f4f15-4239-4adc-b404-49c1baad8cd6/small/ei4change-transparent-background-300x283-png.png https://www.healthreportequatorialguinea.com/article/913020523-microbot-medical-to-hold-analysts-and-investors-conference-call-to-review-recent-progress-executive-team-will-be-joined-by-current-users-of-the Health Report Equatorial Guinea en PressRelease 2026-05-15T13:56:07+00:00 Microbot Medical to Hold Analysts and Investors Conference Call to Review Recent Progress; Executive Team will be Joined by Current Users of the LIBERTY Endovascular Robotic System, Dr. Charles Briggs and Dr. Zachary Bercu https://ml.globenewswire.com/media/346df7fb-c134-40c2-970a-39bcbaf974cd/small/mbot-logo-rgb-jpg.jpg https://www.healthreportequatorialguinea.com/article/913020465-ai-and-advanced-diagnostics-transform-cancer-detection-market-amid-rising-healthcare-investment Health Report Equatorial Guinea en PressRelease 2026-05-15T13:49:09+00:00 AI and Advanced Diagnostics Transform Cancer Detection Market Amid Rising Healthcare Investment https://ml.globenewswire.com/media/d0c282b6-d496-45a8-a941-33fa5c3e824c/small/bcc-logo-1200-630-png.png https://www.healthreportequatorialguinea.com/article/913019838-recludix-pharma-announces-preclinical-data-demonstrating-efficacy-comparable-to-monoclonal-antibodies-targeting-il-4-il-13-signaling-pathways-and Health Report Equatorial Guinea en PressRelease 2026-05-15T13:45:00+00:00 Recludix Pharma Announces Preclinical Data Demonstrating Efficacy Comparable to Monoclonal Antibodies Targeting IL-4/IL-13 Signaling Pathways and Differentiated Safety Profile of Oral STAT6 Inhibitor REX-8756 (also known as SAR448755) in a Model of… https://ml.globenewswire.com/media/b1933b80-b406-4e18-8148-a4b3c6ad2d98/small/recludix-logo-rbg-jpg.jpg https://www.healthreportequatorialguinea.com/article/913020398-federal-court-motion-raises-questions-about-testimony-and-outpatient-hysteroscopy-practices-in-case-against-memphis-gynecologic-surgeon-dr-sanjeev Health Report Equatorial Guinea en PressRelease 2026-05-15T13:25:56+00:00 Federal Court Motion Raises Questions About Testimony and Outpatient Hysteroscopy Practices in Case Against Memphis Gynecologic Surgeon Dr. Sanjeev Kumar https://ml.globenewswire.com/media/65ade942-bb4a-4df2-b797-b8d6a28b0436/medium/olympus-flexible-endoscope-cleaning-disinfection-guide.png https://www.healthreportequatorialguinea.com/article/913020368-psyence-biomed-announces-u-s-strategic-engagement-initiative-focused-on-gmp-ibogaine-research-and-manufacturing Health Report Equatorial Guinea en PressRelease 2026-05-15T13:15:00+00:00 Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing https://ml.globenewswire.com/media/256a2527-4c30-46a1-a4d4-f37c89cfbff2/small/psyence-logo-jpg.jpg https://www.healthreportequatorialguinea.com/article/913019871-recor-medical-highlights-innovation-and-global-action-on-world-hypertension-day-2026 Health Report Equatorial Guinea en PressRelease 2026-05-15T13:00:00+00:00 Recor Medical Highlights Innovation and Global Action on World Hypertension Day 2026 https://ml.globenewswire.com/media/Mjc2NTk4NzgtOTgzZC00MTgzLTgwZGYtMzczZGU1NDYxNzY4LTEzMDExNDgtMjAyNi0wNS0xNS1lbg==/tiny/Recor-Medical.png https://www.healthreportequatorialguinea.com/article/913020024-vaso-corporation-announces-financial-results-for-first-quarter-of-2026 Health Report Equatorial Guinea en PressRelease 2026-05-15T13:00:00+00:00 Vaso Corporation Announces Financial Results for First Quarter of 2026 https://ml.globenewswire.com/media/a9aed35c-c8bb-4592-b2f9-8e9839796cc2/small/vaso-logo-png.png https://www.healthreportequatorialguinea.com/article/913020210-sana-biotechnology-announces-sale-of-approximately-69-million-of-shares-through-its-at-the-market-atm-facility Health Report Equatorial Guinea en PressRelease 2026-05-15T13:00:00+00:00 Sana Biotechnology Announces Sale of Approximately $69 Million of Shares Through its At-the-Market (ATM) Facility https://ml.globenewswire.com/media/2e5b81be-ddf0-4a60-85f1-3f17c242e8c2/small/sana-biotechnology-jpg.jpg https://www.healthreportequatorialguinea.com/article/913020300-oncotelic-therapeutics-files-first-quarter-2026-financial-results-and-strategic-progress Health Report Equatorial Guinea en PressRelease 2026-05-15T13:00:00+00:00 Oncotelic Therapeutics Files First Quarter 2026 Financial Results and Strategic Progress https://ml.globenewswire.com/media/7f42d651-bcd6-4db2-afec-883ab74cfa35/small/logo-png.png https://www.healthreportequatorialguinea.com/article/913020284-propanc-biopharma-provides-corporate-update-and-reports-third-quarter-2025-26-results Health Report Equatorial Guinea en PressRelease 2026-05-15T12:45:00+00:00 Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results https://ml.globenewswire.com/media/0de2a486-4708-45bf-a406-f462ad395dec/small/propanc-logo-png.png https://www.healthreportequatorialguinea.com/article/913020333-60-degrees-pharmaceuticals-announces-first-quarter-2026-results Health Report Equatorial Guinea en PressRelease 2026-05-15T12:42:00+00:00 60 Degrees Pharmaceuticals Announces First Quarter 2026 Results https://ml.globenewswire.com/media/c950cab5-27b1-476f-befc-4d92a7389fdd/small/60degrees-logo-rgb-logo-jpg.jpg https://www.healthreportequatorialguinea.com/article/913020250-clearmind-medicine-ceo-dr-adi-zuloff-shani-named-delegate-to-federal-policy-summit-on-psychedelic-medicine-in-washington-d-c Health Report Equatorial Guinea en PressRelease 2026-05-15T12:35:00+00:00 Clearmind Medicine CEO Dr. Adi Zuloff-Shani named Delegate to Federal Policy Summit on Psychedelic Medicine in Washington, D.C. https://ml.globenewswire.com/media/bd17cbf4-8124-4f86-8a4c-1fafbb6785af/small/logo-jpg.jpg https://www.healthreportequatorialguinea.com/article/913019837-sienna-announces-may-dividend Health Report Equatorial Guinea en PressRelease 2026-05-15T12:30:00+00:00 Sienna Announces May Dividend https://ml.globenewswire.com/media/ac969f39-0111-4903-8faa-0cdee524eb4e/small/sienna-logo-rgb-jpg.jpg https://www.healthreportequatorialguinea.com/article/913020030-srx-health-solutions-announces-board-approval-to-dividend-75-of-profits-from-investment-in-astro-investment-xvii-an-affiliate-of-astro-capital-and Health Report Equatorial Guinea en PressRelease 2026-05-15T12:30:00+00:00 SRx Health Solutions Announces Board Approval to Dividend 75% of Profits from Investment in Astro Investment XVII, an Affiliate of Astro Capital and SPV with Investments in SpaceX and Other Artificial Intelligence and Space Companies https://ml.globenewswire.com/media/768807fe-a29b-48f5-be44-977c8eaf49f0/small/srxlogo-jpg.jpg https://www.healthreportequatorialguinea.com/article/913020091-cytodyn-to-present-at-the-ld-micro-invitational-xvi Health Report Equatorial Guinea en PressRelease 2026-05-15T12:30:00+00:00 CytoDyn to Present at the LD Micro Invitational XVI https://ml.globenewswire.com/media/3b426b4d-6299-4c23-9f95-058174a5b7be/small/new-logo-png.png https://www.healthreportequatorialguinea.com/article/913020183-cormedix-therapeutics-to-participate-in-two-upcoming-investor-conferences Health Report Equatorial Guinea en PressRelease 2026-05-15T12:30:00+00:00 Cormedix Therapeutics to Participate in two Upcoming Investor Conferences https://ml.globenewswire.com/media/a14d732c-3f66-4a3c-96bb-7fc8ba5797bb/small/crmd-logo-jpg.jpg https://www.healthreportequatorialguinea.com/article/913020255-moleculin-reports-first-quarter-2026-financial-results-and-provides-clinical-update-on-pivotal-miracle-trial Health Report Equatorial Guinea en PressRelease 2026-05-15T12:30:00+00:00 Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial https://ml.globenewswire.com/media/7fa09722-2ef8-49fc-bc24-6b150093f8ba/small/mbrx-logo-png.png https://www.healthreportequatorialguinea.com/article/913020278-jyong-biotech-ltd-files-annual-report-on-form-20-f-for-fiscal-year-2025 Health Report Equatorial Guinea en PressRelease 2026-05-15T12:30:00+00:00 Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025 https://ml.globenewswire.com/media/a1e08c1c-37e5-4fa0-bc16-0b603810bf0a/small/logo-png.png https://www.healthreportequatorialguinea.com/article/913019824-silexion-therapeutics-announces-exercise-of-warrants-for-1-million-gross-proceeds Health Report Equatorial Guinea en PressRelease 2026-05-15T12:27:23+00:00 Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds https://ml-eu.globenewswire.com/media/1070dc42-db79-4712-af48-38ffbdf3b140/small/screenshot-2025-05-13-at-15-29-06-png.png https://www.healthreportequatorialguinea.com/article/913019914-obagi-medical-shares-new-data-on-recent-innovations-at-music-city-symposium-for-cosmetic-advances-laser-education-scale-meeting Health Report Equatorial Guinea en PressRelease 2026-05-15T12:13:00+00:00 Obagi Medical Shares New Data on Recent Innovations at Music City Symposium for Cosmetic Advances & Laser Education (SCALE) Meeting https://ml.globenewswire.com/media/b627cdd5-09af-4bd4-8b16-25f629cf422e/small/waldencast-logo-png.png https://www.healthreportequatorialguinea.com/article/913002961-research-highlights-diet-and-hormone-therapy-advances-in-preventing-recurrent-utis-in-women Health Report Equatorial Guinea en PressRelease 2026-05-15T12:00:00+00:00 Research Highlights Diet and Hormone Therapy Advances in Preventing Recurrent UTIs in Women https://ml.globenewswire.com/media/YTI5MWJiN2ItMmNkNS00NjViLWFiMTMtMGNkOTE4MjM1ZGM3LTEyNzYxOTAtMjAyNi0wNS0xNS1lbg==/tiny/American-Urological-Associatio.png https://www.healthreportequatorialguinea.com/article/913002974-galectin-therapeutics-reports-march-31-2026-financial-results-and-provides-business-update Health Report Equatorial Guinea en PressRelease 2026-05-15T12:00:00+00:00 Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update https://ml.globenewswire.com/media/dd593f5d-61a4-4e6b-87d3-b9deb9f5d33f/small/galectin-jpg.jpg https://www.healthreportequatorialguinea.com/article/913003064-inmune-bio-publishes-phase-2-mindful-trial-results-in-npj-dementia-advancing-the-xpro-platform Health Report Equatorial Guinea en PressRelease 2026-05-15T12:00:00+00:00 INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro™ Platform https://ml.globenewswire.com/media/64035ec0-9fc2-414d-a693-27f1b1e90a31/small/logo-png.png https://www.healthreportequatorialguinea.com/article/913003112-cg-oncology-reports-positive-first-results-from-core-008-cohort-cx-phase-2-trial-evaluating-intravesical-combination-therapy-in-high-risk-bcg-exposed Health Report Equatorial Guinea en PressRelease 2026-05-15T12:00:00+00:00 CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients https://ml.globenewswire.com/media/9e1cbdea-928e-4ea4-b4cd-33cdc36c6b2f/small/cgoncology-cover-jpg.jpg https://www.healthreportequatorialguinea.com/article/913003216-atyr-pharma-announces-first-quarter-2026-results-and-provides-corporate-update Health Report Equatorial Guinea en PressRelease 2026-05-15T12:00:00+00:00 aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update https://ml.globenewswire.com/media/d9b4b478-f8bd-4014-91ed-429caab67931/small/atyr-logo-png.png https://www.healthreportequatorialguinea.com/article/913003220-cocrystal-pharma-provides-business-update-and-reports-first-quarter-2026-financial-results Health Report Equatorial Guinea en PressRelease 2026-05-15T12:00:00+00:00 Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results https://ml.globenewswire.com/media/a5071a3a-c592-43ba-bfee-77c2867982ba/small/cocrystal-logo-final-highres-792x612-png.png https://www.healthreportequatorialguinea.com/article/913003300-urogen-reports-94-5-six-month-duration-of-response-in-phase-3-utopia-trial-advancing-ugn-103-toward-potential-approval-in-recurrent-low-grade Health Report Equatorial Guinea en PressRelease 2026-05-15T12:00:00+00:00 UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC https://ml.globenewswire.com/media/8b4e2813-5822-438f-a0d8-1a2c99628858/small/urogen-logo2-r-002-png.png https://www.healthreportequatorialguinea.com/article/913003357-biocardia-reports-first-quarter-2026-business-highlights-and-financial-results Health Report Equatorial Guinea en PressRelease 2026-05-15T12:00:00+00:00 BioCardia Reports First Quarter 2026 Business Highlights and Financial Results https://ml.globenewswire.com/media/4641bb53-4913-4654-a337-79383a5c7ab9/small/biocardia-final-logo-2016-jpeg-jpg.jpg https://www.healthreportequatorialguinea.com/article/913003361-lifemd-to-participate-in-upcoming-investor-conferences Health Report Equatorial Guinea en PressRelease 2026-05-15T12:00:00+00:00 LifeMD to Participate in Upcoming Investor Conferences https://ml.globenewswire.com/media/07c92c99-5645-4be8-a3b7-6d9392b7ccc4/small/lifemd-png.png https://www.healthreportequatorialguinea.com/article/913003373-belite-bio-announces-oral-presentation-at-the-27th-fundus-disease-forum-and-international-retinal-symposium-retina-china-2026 Health Report Equatorial Guinea en PressRelease 2026-05-15T12:00:00+00:00 Belite Bio Announces Oral Presentation at the 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026) https://ml.globenewswire.com/media/7f86ac70-6347-41c6-a622-e7000c42ad35/small/belite-bio-logo-digital-full-color-png.png https://www.healthreportequatorialguinea.com/article/913003410-gt-biopharma-reports-first-quarter-2026-financial-results Health Report Equatorial Guinea en PressRelease 2026-05-15T12:00:00+00:00 GT Biopharma Reports First Quarter 2026 Financial Results https://ml.globenewswire.com/media/d185929e-a134-45e9-beed-5895b902fd3e/small/logo-png.png https://www.healthreportequatorialguinea.com/article/913003419-lifeward-reports-first-quarter-2026-financial-results Health Report Equatorial Guinea en PressRelease 2026-05-15T12:00:00+00:00 Lifeward Reports First Quarter 2026 Financial Results https://ml.globenewswire.com/media/9343d7ac-5bc7-4a60-a2c9-a41bf7b5e007/small/lifeward-full-logo-rgb-for-web-01-jpg.jpg https://www.healthreportequatorialguinea.com/article/913003157-immuneering-reports-first-quarter-2026-financial-results-and-provides-business-updates Health Report Equatorial Guinea en PressRelease 2026-05-15T11:35:00+00:00 Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates https://ml.globenewswire.com/media/81d0c83f-ae53-4d6e-9c5e-d6963e02f29d/small/immuneering-logo-cropped-1-jpg.jpg https://www.healthreportequatorialguinea.com/article/913003186-briacell-expands-pipeline-to-include-an-ovarian-cancer-immunotherapy-candidate-bria-ova Health Report Equatorial Guinea en PressRelease 2026-05-15T11:30:00+00:00 BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™ https://ml.globenewswire.com/media/88b9408d-31d4-4afd-beff-f855719a15d8/small/briacell-logo-square-a-jpg.jpg https://www.healthreportequatorialguinea.com/article/913003206-mink-therapeutics-reports-first-quarter-2026-financial-results-and-advances-inkt-cell-therapy-platform-into-randomized-clinical-validation Health Report Equatorial Guinea en PressRelease 2026-05-15T11:30:00+00:00 MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation https://ml.globenewswire.com/media/6aa8e960-515a-40d6-9894-39ca47f5c84e/small/mink-logo-loyal-blue-and-light-blue-png.png https://www.healthreportequatorialguinea.com/article/913003210-palvella-therapeutics-announces-new-data-from-the-phase-2-toiva-trial-of-qtorin-rapamycin-in-cutaneous-venous-malformations-presented-at-the-83rd Health Report Equatorial Guinea en PressRelease 2026-05-15T11:30:00+00:00 Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology https://ml.globenewswire.com/media/83fd569b-5e6c-46ad-882a-6430f8ab755a/small/palvella-2025-logo-new-jpg.jpg https://www.healthreportequatorialguinea.com/article/913003214-annovis-provides-corporate-updates-and-reports-first-quarter-2026-financial-results Health Report Equatorial Guinea en PressRelease 2026-05-15T11:30:00+00:00 Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results https://ml.globenewswire.com/media/7ee459df-d33f-4f42-b27c-3bd20487d50c/small/annovis-corp-image-png.png https://www.healthreportequatorialguinea.com/article/913003364-profusa-announces-listing-transfer-to-the-nasdaq-capital-market Health Report Equatorial Guinea en PressRelease 2026-05-15T11:30:00+00:00 Profusa Announces Listing Transfer to The Nasdaq Capital Market https://ml.globenewswire.com/media/a8137a61-b858-48da-9e47-1f1bf8f6ddba/small/profusa-logo-jpg.jpg https://www.healthreportequatorialguinea.com/article/913002955-intercontinental-icu-air-ambulance-transport-highlights-growing-need-for-continuous-in-flight-medical-care Health Report Equatorial Guinea en PressRelease 2026-05-15T11:28:02+00:00 Intercontinental ICU Air Ambulance Transport Highlights Growing Need for Continuous In-Flight Medical Care https://ml-eu.globenewswire.com/media/668268d8-a04c-4709-98b8-ecb00ddc615d/medium/interior-air-ambulance-repatriation.jpg https://www.healthreportequatorialguinea.com/article/913002952-davos-alzheimer-s-collaborative-celebrates-andrea-pfeifer-retiring-ceo-of-ac-immune-for-her-contributions-to-alzheimer-s-policy-research-and-care Health Report Equatorial Guinea en PressRelease 2026-05-15T11:01:20+00:00 Davos Alzheimer’s Collaborative Celebrates Andrea Pfeifer, Retiring CEO of AC Immune, for Her Contributions to Alzheimer’s Policy, Research and Care https://ml-eu.globenewswire.com/media/186fa966-473e-4519-b482-432f708899b3/small/screenshot-2026-05-14-at-22-23-39-davos-alzheimers-collabora.png https://www.healthreportequatorialguinea.com/article/913003039-kanghong-pharmaceutical-and-vanotech-announce-positive-phase-2b-results-for-kh607-in-major-depressive-disorder Health Report Equatorial Guinea en PressRelease 2026-05-15T11:00:00+00:00 Kanghong Pharmaceutical and Vanotech Announce Positive Phase 2b Results for KH607 in Major Depressive Disorder https://ml.globenewswire.com/media/YWI5ZTk5NWMtNzBmZS00NmM3LTkyMmEtYThhYzJhNjA1YjY0LTEyNzYwMTEtMjAyNi0wNS0xNS1lbg==/tiny/Vanotech-Ltd.png https://www.healthreportequatorialguinea.com/article/913003058-protara-therapeutics-announces-positive-updated-12-month-data-demonstrating-durable-responses-in-the-fully-enrolled-bcg-na-ve-cohort-of-the-ongoing Health Report Equatorial Guinea en PressRelease 2026-05-15T11:00:00+00:00 Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC https://ml.globenewswire.com/media/ba98d7ed-6917-452d-a864-6f60caa53c1b/small/protara-therapeutics-2x-png.png https://www.healthreportequatorialguinea.com/article/913003139-instil-bio-reports-first-quarter-2026-financial-results-and-provides-corporate-update Health Report Equatorial Guinea en PressRelease 2026-05-15T11:00:00+00:00 Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update https://ml.globenewswire.com/media/f498b1db-364d-434d-bef0-a12d931bcda2/small/instil-bio-logo-png.png https://www.healthreportequatorialguinea.com/article/913003147-kymera-therapeutics-announces-presentations-on-kt-621-a-first-in-class-oral-stat6-degrader-at-the-society-for-investigative-dermatology-and Health Report Equatorial Guinea en PressRelease 2026-05-15T11:00:00+00:00 Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses https://ml.globenewswire.com/media/4d3d3283-c57d-401e-9e1b-53f17e22d76b/small/kymera-logo-rgb-denim-marigold-high-res-png.png https://www.healthreportequatorialguinea.com/article/913003174-traws-pharma-provides-business-highlights-and-reports-q1-2026-financial-results Health Report Equatorial Guinea en PressRelease 2026-05-15T11:00:00+00:00 Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results https://ml.globenewswire.com/media/1eb1780a-724e-4555-ab4d-455e27d18544/small/traws-pharma-blue-png.png https://www.healthreportequatorialguinea.com/article/913003191-ocular-therapeutix-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4 Health Report Equatorial Guinea en PressRelease 2026-05-15T11:00:00+00:00 Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/20ee0f50-7288-4f81-8546-f2ad2050ddbf/small/ocul-logo-jpg.jpg https://www.healthreportequatorialguinea.com/article/913003199-bioxcel-therapeutics-provides-business-update-and-reports-first-quarter-2026-financial-results Health Report Equatorial Guinea en PressRelease 2026-05-15T11:00:00+00:00 BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results https://ml.globenewswire.com/media/63fea215-2cfc-4e2b-b169-43dcfff60b34/small/btai-logo-png-220x123-png.png https://www.healthreportequatorialguinea.com/article/913003213-satellos-reports-first-quarter-2026-financial-results-and-highlights-company-progress Health Report Equatorial Guinea en PressRelease 2026-05-15T11:00:00+00:00 Satellos Reports First Quarter 2026 Financial Results and Highlights Company Progress https://ml.globenewswire.com/media/3fe5e759-e0bb-4bc7-9979-e58a67f5f684/small/satellos-logo-gradient-black-png.png https://www.healthreportequatorialguinea.com/article/913003353-indaptus-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update Health Report Equatorial Guinea en PressRelease 2026-05-15T11:00:00+00:00 Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update https://ml.globenewswire.com/media/92abd56f-6fef-4376-9bd9-813febf90ecc/small/indaptus-logo-png.png https://www.healthreportequatorialguinea.com/article/913003245-telix-announces-collaborations-to-explore-psma-pet-imaging-in-emerging-prostate-cancer-treatment-approaches Health Report Equatorial Guinea en PressRelease 2026-05-15T10:30:00+00:00 Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches https://ml.globenewswire.com/media/77ceffdf-31cc-415f-9747-efee950af329/small/telix-main-logo-3-png.png https://www.healthreportequatorialguinea.com/article/912986496-positive-interim-data-from-cohorts-1-and-2-of-tenaya-s-ridge-1-phase-1b-2-clinical-trial-of-tn-401-demonstrated-consistent-reductions-in-arrhythmia Health Report Equatorial Guinea en PressRelease 2026-05-15T10:01:00+00:00 Positive Interim Data from Cohorts 1 and 2 of Tenaya’s RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with PKP2-associated ARVC https://ml.globenewswire.com/media/95a7de9f-2b24-4ff3-9b57-f8a35e8c049f/small/tenaya-logo-fullcolor-rgb-jpg.jpg https://www.healthreportequatorialguinea.com/article/912986493-ars-pharmaceuticals-reports-first-quarter-2026-financial-results-and-corporate-update Health Report Equatorial Guinea en PressRelease 2026-05-15T10:00:00+00:00 ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update https://ml.globenewswire.com/media/8feeb9d1-ed0c-491a-988b-a2b54778e825/small/ars-logo-png.png https://www.healthreportequatorialguinea.com/article/912986540-umbrella-lab-announces-documentation-and-traceability-update-for-ipamorelin-peptide Health Report Equatorial Guinea en PressRelease 2026-05-15T09:05:49+00:00 Umbrella Lab Announces Documentation And Traceability Update For Ipamorelin Peptide https://ml.globenewswire.com/media/3b8f69f9-c12e-4800-8809-11d63000c38d/medium/umbrella-lab.jpg https://www.healthreportequatorialguinea.com/article/912926616-desert-hope-treatment-center-welcomes-alumni-coordinator-whose-recovery-journey-began-in-its-program Health Report Equatorial Guinea en PressRelease 2026-05-15T01:00:00+00:00 Desert Hope Treatment Center Welcomes Alumni Coordinator Whose Recovery Journey Began in Its Program https://ml.globenewswire.com/media/6d42b423-29cf-4b7a-b1d4-383db7bd1078/medium/madot-gebreegziabher.jpg https://www.healthreportequatorialguinea.com/article/912884982-biosyent-declares-second-quarter-2026-dividend Health Report Equatorial Guinea en PressRelease 2026-05-14T22:01:00+00:00 BioSyent Declares Second Quarter 2026 Dividend https://ml.globenewswire.com/media/3dded277-7953-4418-be63-7d7a3067811d/small/biosyent-logo-png.png https://www.healthreportequatorialguinea.com/article/912885672-sol-sence-supports-landmark-report-on-uv-safety-in-the-united-kingdom-as-member-of-uv-safety-coalition Health Report Equatorial Guinea en PressRelease 2026-05-14T22:00:29+00:00 Solésence Supports Landmark Report on UV Safety in the United Kingdom as Member of UV Safety Coalition https://ml.globenewswire.com/media/0ce1f2dd-8447-4b3f-8f4f-18dcb6769641/medium/solesence-with-chair-of-appg-for-beauty-hair-wellbeing-and-t.jpg https://www.healthreportequatorialguinea.com/article/912885636-biosyent-releases-financial-results-for-first-quarter-2026 Health Report Equatorial Guinea en PressRelease 2026-05-14T22:00:00+00:00 BioSyent Releases Financial Results for First Quarter 2026 https://ml.globenewswire.com/media/3dded277-7953-4418-be63-7d7a3067811d/small/biosyent-logo-png.png https://www.healthreportequatorialguinea.com/article/912885616-glucotrack-reports-first-quarter-2026-financial-results-and-recent-corporate-highlights Health Report Equatorial Guinea en PressRelease 2026-05-14T21:27:07+00:00 Glucotrack Reports First Quarter 2026 Financial Results and Recent Corporate Highlights https://ml.globenewswire.com/media/bafad597-388b-4b55-bab1-535713ff1321/small/logo-png.png https://www.healthreportequatorialguinea.com/article/912885540-lixte-biotechnology-files-first-quarter-2026-quarterly-report-on-form-10-q-provides-operational-progress-update Health Report Equatorial Guinea en PressRelease 2026-05-14T21:18:00+00:00 LIXTE Biotechnology Files First Quarter 2026 Quarterly Report on Form 10-Q; Provides Operational Progress Update https://ml.globenewswire.com/media/7e828ef4-6c8f-4c94-b376-4e3749530fba/small/logo-jpg.jpg